Northwest Biotherapeutics Inc - Current report filing (8-K)
August 12 2008 - 6:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported): August 12, 2008
NORTHWEST BIOTHERAPEUTICS,
INC.
(Exact name of registrant as
specified in its charter)
|
|
|
|
|
DELAWARE
|
|
0-33393
|
|
94-3306718
|
(State or other Jurisdiction of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
7600 Wisconsin Avenue, Suite
750, Bethesda, MD
|
|
20814
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number,
including area code:
(240) 497-9024
|
|
(Former name or former address if changed since last report.)
|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
Item 5.02. Departure of
Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
Effective August 12, 2008, Anthony
P. Deasey resigned as Senior Vice President of Finance, Chief Financial Officer
and ex officio Director of Northwest Biotherapeutics, Inc. (the
“Company”) in order to pursue a personal entrepreneurial
opportunity. Day to day responsibilities related to the Company’s
accounting and financial administration will remain with the Company
controller. Other financial functions, including pursuit of funding
opportunities, will be carried out by the Company’s Chief Executive
Officer, Dr. Alton Boynton, and the Company’s Chairperson,
Ms. Linda Powers. Although Mr. Deasey will discontinue his roles as
an officer and ex officio director of the Company effective August 12, 2008,
Mr. Deasey’s employment with the Company will continue until
September 30, 2008, to help with the transition. In addition, from
October 1, 2008, through November 15, 2008, Mr. Deasey will
provide part-time consulting services to the Company, and will receive
consulting fees at a rate equal to 50% of his current monthly salary.
SIGNATURES
Pursuant to the
requirements of Section 12 of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
August 12, 2008
|
|
NORTHWEST BIOTHERAPEUTICS, INC.
|
|
|
|
By
|
|
/s/ Alton L. Boynton
|
|
|
|
|
|
|
|
|
|
Alton L. Boynton
|
|
|
|
|
President & Chief Executive
Officer
|
|
|
|
|
|
2
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Jul 2023 to Jul 2024